This summer, agrochemical, biotechnology and seed giant Monsanto dropped its bid to acquire its Switzerland-based competitor, Syngenta. Initial merger serenades were sternly rebuffed by Syngenta, ...

Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), a biotechnology company with a market capitalization of $2.5 billion, recently executed a series of stock transactions, ...

New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

Budget amendments from the governor and the House of Delegates both include $5 million in funding for the Roanoke project.

This is common. Those of us in research routinely store patient samples — blood, fluids, tissue, scrapings, and other ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Corteva's genetically modified Enlist platform has had wins over Bayer in recent years in gaining approval for its GMO seeds to be imported into China, which should boost Enlist's market share.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...